Abstract
Introduction: The role of magnesium in treating arrhythmias due to acute myocardial infarction (AMI) has been controversial. Most of the studies have reported a significant reduction in the mortality and frequency of arrhythmias in patients with AMI, who received magnesium therapy, in comparison with control with AMI, who did not receive magnesium treatment. We, therefore, decided that we would evaluate the effect of intravenous magnesium supplement therapy in patients admitted for acute myocardial infarction and if this would be helpful in reducing the morbidity and mortality in patients. Materials and Methods: The study was carried out as a prospective randomized controlled trial of magnesium therapy in acute myocardial infarction. Hundred patients with acute myocardial infarction were randomly divided into two groups of 50 patients each, one for trial and other for placebo therapy. Control group consisted of 20 healthy volunteers of the same age group. All of the 100 patients included in the study had reported within 12 hours of the onset of chest pain. Blood samples for estimation of serum magnesium were taken on admission and on days 2 and 5. Results: The mean age in the Group I and II were 59.52 years ± 15.03 and 59.14 years ± 13.41, respectively. Serum magnesium level on admission was higher in the healthy controls than in the patients of acute myocardial infarction ( P P Conclusions: Intravenous magnesium is a safe and effective method of reducing the frequency of arrhythmias and mortality following the acute myocardial infarction. Magnesium therapy reduces the incidence of arrhythmias and mortality even in the absence of demonstrable magnesium deficiency.
Highlights
Serum magnesium level on admission was higher in the healthy controls than in the patients of acute myocardial infarction (P < 0.0001)
Magnesium therapy reduces the incidence of arrhythmias and mortality even in the absence of demonstrable magnesium deficiency
Serum magnesium level on admission was higher in the healthy controls than in the patients of acute myocardial infarction [Table 1]
Summary
Institute of Medical Sciences University, Dhebewadi Road, Introduction: The role of magnesium in treating arrhythmias due to acute myocardial infarction (AMI) has been controversial. Most of the studies have reported a significant reduction in the mortality and frequency of arrhythmias in patients with AMI, who received magnesium therapy, in comparison with control with AMI, who did not receive magnesium treatment. We, therefore, decided that we would evaluate the effect of intravenous magnesium supplement therapy in patients admitted for acute myocardial infarction and if this would be helpful in reducing the morbidity and mortality in patients. Materials and Methods: The study was carried out as a prospective randomized controlled trial of magnesium therapy in acute myocardial infarction. Hundred patients with acute myocardial infarction were randomly divided into two groups of 50 patients each, one for trial and other for placebo therapy. Control group consisted of 20 healthy volunteers of the same age group. All of the 100 patients included in the study had reported within 12 hours of the onset of chest pain. Blood samples for estimation of serum magnesium were taken on admission and on days 2 and
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: International Journal of Medicine and Public Health
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.